IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.479
NA - Nord America 3.147
AS - Asia 2.580
SA - Sud America 736
AF - Africa 60
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 5
Totale 10.021
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.063
IE - Irlanda 1.244
SG - Singapore 1.218
RU - Federazione Russa 643
BR - Brasile 602
IT - Italia 462
HK - Hong Kong 417
SE - Svezia 393
CN - Cina 362
VN - Vietnam 287
FR - Francia 239
DE - Germania 162
FI - Finlandia 104
GB - Regno Unito 74
AR - Argentina 52
IN - India 43
IR - Iran 42
CA - Canada 37
BD - Bangladesh 34
EC - Ecuador 32
ES - Italia 32
IQ - Iraq 29
NL - Olanda 28
PL - Polonia 28
MX - Messico 26
TR - Turchia 26
ID - Indonesia 21
ZA - Sudafrica 16
JP - Giappone 15
AT - Austria 14
PK - Pakistan 13
AU - Australia 12
CO - Colombia 11
EG - Egitto 11
PY - Paraguay 11
SA - Arabia Saudita 10
VE - Venezuela 10
MA - Marocco 9
BE - Belgio 8
UZ - Uzbekistan 8
CL - Cile 7
UA - Ucraina 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
CR - Costa Rica 6
KZ - Kazakistan 6
OM - Oman 6
DO - Repubblica Dominicana 5
NP - Nepal 5
RO - Romania 5
UY - Uruguay 5
DZ - Algeria 4
GR - Grecia 4
JO - Giordania 4
KE - Kenya 4
PE - Perù 4
PH - Filippine 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
JM - Giamaica 3
LB - Libano 3
LT - Lituania 3
PS - Palestinian Territory 3
TN - Tunisia 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DK - Danimarca 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
KW - Kuwait 2
MD - Moldavia 2
MK - Macedonia 2
PA - Panama 2
QA - Qatar 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BG - Bulgaria 1
BW - Botswana 1
ET - Etiopia 1
GE - Georgia 1
KG - Kirghizistan 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MY - Malesia 1
NE - Niger 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
Totale 10.015
Salva come PNG Salva come JPEG
Città #
Dublin 1.242
San Jose 739
Chandler 491
Singapore 430
Hong Kong 407
Nyköping 327
Ashburn 311
Santa Clara 175
Beijing 170
Lauterbourg 148
Princeton 134
Ho Chi Minh City 106
Wilmington 84
Helsinki 82
São Paulo 58
Munich 55
Frankfurt am Main 48
Hanoi 42
Dallas 36
Rome 35
New York 34
Des Moines 32
Los Angeles 32
Milan 28
Moscow 26
Shiraz 26
Hillsboro 23
Warsaw 23
Bari 22
Turku 22
Ann Arbor 21
Nuremberg 21
Rio de Janeiro 21
Naples 20
Orem 20
Seattle 20
Serra de' Conti 20
London 17
Curitiba 15
Paris 15
Brooklyn 14
Tokyo 14
Assago 13
Granada 13
Thái Bình 13
Brasília 12
Foggia 12
Guangzhou 12
Montreal 12
Bexley 11
Chicago 11
Denver 11
Falkenstein 11
Belo Horizonte 10
Biên Hòa 10
Düsseldorf 10
Palermo 10
Quito 10
San Francisco 10
The Dalles 10
Cedar Knolls 9
Karachi 9
Ninh Bình 9
Washington 9
Baghdad 8
Campinas 8
Can Tho 8
Council Bluffs 8
Da Nang 8
Kocaeli 8
Madrid 8
Porto Alegre 8
Shanghai 8
Stockholm 8
Boston 7
Buenos Aires 7
Guayaquil 7
Jiaxing 7
Riyadh 7
Toronto 7
Vienna 7
Amsterdam 6
Atlanta 6
Cairo 6
Chennai 6
Fortaleza 6
Guarulhos 6
Hải Dương 6
Johannesburg 6
Juiz de Fora 6
Melbourne 6
Mexico City 6
Pune 6
San José 6
Santo André 6
St Louis 6
Tashkent 6
Tehran 6
Alessandria 5
Ankara 5
Totale 6.084
Salva come PNG Salva come JPEG
Nome #
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 218
Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 113
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 110
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 108
Approccio clinico e possibilità di trattamento nella SLA 107
CCSVI and MS. A population-based case-control study in Catania, Sicily 106
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 103
An update on the pharmacological management of pain in patients with multiple sclerosis 102
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 95
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 94
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 94
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 92
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal 92
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 92
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 91
Association between dietary intake and function in amyotrophic lateral sclerosis 90
Can new chemical therapies improve the management of multiple sclerosis in children? 89
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 88
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 88
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 87
Dysphagia in Multiple Sclerosis 87
Comparison of Two Therapeutic Strategies in Active Relapsing-Remitting MS: Cyclophosphamide as Induction for 12 Months Follewed by Interferon Beta Versus Interferon Beta. A Two-Year Randomized Trial 87
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 87
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 86
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 86
Psychological and social findings of patients with early multiple sclerosis or clinically isolated syndrome 85
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 85
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 85
Review: Patient-reported outcomes in multiple sclerosis care 85
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 83
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 83
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 83
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 83
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 82
Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy 82
Use of a low-cost, commercially available gaming console (Nintendo-WII) foe rehabilitation of patients with multiple sclerosis: results of a pilot study 81
Employment status in MS patients: a population-based study 81
Neuropsychological pattern of cognitive dysfunction in clinically isolated syndrome suggestive of MS 80
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis 79
An update on the safety of treating relapsing-remitting multiple sclerosis 79
The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS 79
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 79
Effects of inpatient and outpatient rehabilitation setting on disability and quality of life of patients with multiple sclerosis: a randomized controlled study 78
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 78
The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 78
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 77
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 76
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study 76
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 76
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 76
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 75
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 75
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 74
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 74
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 74
Negative prognostic impact of spinal demyelinating lesions at clinical onset in relapsing-remitting multiple sclerosis 74
Unsatisfactory clinical and MRI response to DMTS in patients with late onset relapsing-remitting MS 73
Multiple sclerosis patients preferences in decision making process 72
Management of dysphagia in multiple sclerosis: current best practice 72
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 71
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 71
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 70
Prevalence of pain in multiple sclerosis: a multicenter italian study 70
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 69
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 69
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 69
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 69
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 68
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 68
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 67
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 67
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 66
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 66
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 65
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 65
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 64
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 64
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 64
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 64
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 64
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 64
Five insights from the Global Burden of Disease Study 2019 63
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 63
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 63
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 63
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 63
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 63
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 63
Myeloid-derived Suppressor Cells and Multiple Sclerosis 62
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 62
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 62
Palliative care in progressive multiple sclerosis 62
Gender related side effects of interferon-beta treatment in multiple sclerosis patients 62
Dietary Phenolic Acids and Their Major Food Sources Are Associated with Cognitive Status in Older Italian Adults 60
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 60
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 59
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 59
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 59
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 59
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 58
Totale 7.803
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.282
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.282
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 24 0 1
2021/2022893 5 0 1 0 363 30 14 47 97 93 21 222
2022/20232.663 270 115 199 121 48 210 16 182 1.373 45 52 32
2023/2024480 57 47 31 32 75 58 30 52 26 19 19 34
2024/20252.309 110 72 68 42 41 265 341 107 586 150 230 297
2025/20264.375 213 529 582 887 186 134 716 448 471 209 0 0
Totale 10.745